BioCentury
ARTICLE | Clinical News

FDA approves Aclaris' Eskata to treat SK

December 22, 2017 7:53 PM UTC

Aclaris Therapeutics Inc. (NASDAQ:ACRS) said FDA approved Eskata hydrogen peroxide topical solution 40% to treat raised seborrheic keratosis (SK).

Aclaris plans to launch Eskata in the U.S. in spring 2018. It will be available as a self-pay aesthetic treatment. ...

BCIQ Company Profiles

Aclaris Therapeutics Inc.